You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: CIR
News: Latest news
Web Site: Circadian Technologies Limited
Other Articles: 20-08-201006-05-201015-04-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 08:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 01:02TD Bank posts 29% increase in Q3 profits on strong retail earnings growth

"Our third quarter results really tell the growth story of our retail businesses on both sides of the border, with our total adjusted retail earnings hitting a new high of $1.3 billion, up 21% from last year," said president and CEO Ed Clark.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Circadian Technologies Limited

Circadian Technologies Limited

Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses. Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.

CLICK HERE FOR FULL ANALYSIS OF CIRCADIAN TECHNOLOGIES LIMITED
Wednesday, March 10, 2010

US Broker: "Circadian Technologies The Cheapest Little Antibody Company on the Planet"

by Proactive Investors company news image

US-based investment bank Merriman Curhan Ford has issued a research report on local biotechnology company Circadian Technologies (ASX: CIR) with a BUY rating and a A$2.20-2.88 price per share target range.

The Circadian share price currently sits at A$0.63.

52-Week Range: $0.56-0.88
Cash (M): $34.8
Book Value/Share: $0.86
Market Cap (M): $29

Merriman Curhan Ford Investment Conclusion

Circadian Technologies is a developmental stage biotech company mainly focuses on the development of antibodies for the treatment of cancer. The company possesses a basket of validated preclinical assets and a strong patent estate. Current valuation provides an attractive entry point for investors interested in an inexpensive antibody company.

The shares are trading well below cash (AUD 0.75/share) and are poised to see near term potential upside on the basis of the company’s minority stake in Antisense Therapeutics, which is on the cusp of a milestone.

We are therefore transferring coverage with a Buy rating and a AUD 2.20-2.88 price target range.

Summary

Circadian Technologies: the cheapest antibody play on the planet?

Circadian Technologies Ltd. is an Australia-based antibody development company that might represent the least expensive way for investors to access an investment in the antibody space. Over the past decade, sales of antibody based products have grown exponentially, and a number of antibody technology and therapeutic companies have been acquired.

Circadian represents the rare opportunity to invest in a company that trades at a negative enterprise value and is in an area of great interest to the biotech and pharmaceutical industries.

Covering the VEGF landscape-easy as 1, 2, 3. The VEGF signaling pathway is represented by a family of three receptors and the proteins that bind them (ligands).

Most investors and physicians know about VEGF based on the success of the success Genentech/Roche’s (ROG.VX CHF 179.40; Not Rated) antibody, Avastin. Avastin is directed at the VEGF-A ligand, which binds the VEGF-1 and 2 receptors. In contrast, Circadian is developing antibodies to the ligands VEGF-C and D, which bind the VEGF-2 and 3 receptors.

This mechanism may offer additional efficacy and/or a reduction in resistance compared to traditional anti-angiogenic approaches.

Circadian’s approach is unique, IP position is strong. Circadian has three internal and one out-licensed development candidates targeting VEGF-C and D providing multiple opportunities for success.

The company’s IP position extends out at least to 2025, providing investors with assurance of sustained revenues for the foreseeable future.

Merriman Curhan Ford concluded:

Transferring coverage with a Buy rating. Circadian may be the least expensive publically-traded antibody we can find. At a valuation of AUD 26M, we see significant upside in the shares.

Circadian Technologies Limited, a biotechnology company, engages in the development and commercialization of angiogenesis-based therapies for the treatment of cancer and other human illnesses. It owns intellectual properties related to vascular endothelial growth factors (VEGFs), a class of proteins that regulate tumor blood supply.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other Circadian Technologies Limited articles


Other Circadian Technologies Limited news

More news ►

Investors interested in Circadian Technologies Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.